Community curated by people like you

Valneva stories

Oct 8, 2026

UK revokes marketing authorization for Valneva's IXCHIQ chikungunya vaccine

The UK Medicines and Healthcare products Regulatory Agency has revoked the marketing authorization for Valneva's IXCHIQ chikungunya vaccine following a benefit-risk assessment by the Commission on Human Medicines. The decision caused Valneva shares to fall on Monday.

Oct 8, 2026·3 sources

00

Top claims

▪The UK Medicines and Healthcare products Regulatory Agency revoked the marketing authorization for Valneva SE's Ixchiq chikungunya vaccine following a benefit-risk assessment by the UK Commission on Human Medicines.
▪No Ixchiq product remains on the UK market, and Valneva SE expects no expenses related to a product recall and only minimal impact on its overall sales revenue.
▪Chikungunya vaccination is unnecessary for travelers from non-endemic countries

Topics

Drug safety Infectious disease prevention

Related entities